BRCA1 and prostate adenocarcinoma: Despite that RNA-seq may benefit PRAD patients by detecting fusions (e.g., NTRK), large genomic rearrangements (e.g., BRCA1/2), and splice variants (e.g., AR-V7) that may guide targeted therapies, its low cost-effectiveness may prevent it from being widely used in clinical settings.